Gsa Capital Partners LLP Oric Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	SELL	$5.41 - $9.43 $51,411 - $89,613	-9,503 Reduced 27.94%	24,515 $225,000
Q3 2023 Nov 15, 2023	SELL	$6.05 - $9.28 $517,105 - $793,180	-85,472 Reduced 71.53%	34,018 $205,000
Q2 2023 Aug 14, 2023	SELL	$4.95 - $8.4 $113,429 - $192,486	-22,915 Reduced 16.09%	119,490 $927,000
Q1 2023 May 12, 2023	SELL	$4.26 - $6.75 $408,764 - $647,689	-95,954 Reduced 40.26%	142,405 $811,000
Q4 2022 Feb 13, 2023	BUY	$2.41 - $5.89 $30,749 - $75,150	12,759 Added 5.66%	238,359 $1.4 Million
Q3 2022 Nov 14, 2022	BUY	$3.15 - $5.24 $551,139 - $916,816	174,965 Added 345.54%	225,600 $722,000
Q2 2022 Aug 09, 2022	BUY	$2.7 - $7.07 $21,945 - $57,464	8,128 Added 19.12%	50,635 $227,000
Q1 2022 May 11, 2022	BUY	$4.54 - $16.1 $84,230 - $298,703	18,553 Added 77.45%	42,507 $227,000
Q4 2021 Feb 14, 2022	BUY	$12.01 - $20.3 $287,687 - $486,266	23,954 New	23,954 $352,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.